Europe’s Startups Should Stop Chasing Grants

Why It Matters

Relying on grants at the seed stage hampers Europe’s ability to produce globally competitive science companies and misuses public funds that could be better allocated to scaling validated innovations.

Key Takeaways

• Grants push founders to chase eligibility, not market demand
• Early public money can absorb up to 50% overhead, reducing founder capital
• Private investment first forces product‑market validation and faster growth
• Misaligned funding leads to delayed launches, as seen with Orbex
• Proxima Fusion raised private capital before public support, proving the model

Pulse Analysis

Europe’s deep‑tech ecosystem has long leaned on generous grant programmes to nurture scientific talent. Policymakers view early public funding as a catalyst for industrial sovereignty, and institutions such as Innovate UK and Horizon Europe channel billions into research projects. While this approach fuels foundational work, it also creates a funding culture where scientists tailor their ventures to satisfy bureaucratic criteria rather than address real‑world market needs. The result is a pipeline of technically impressive but commercially untested ventures that struggle to attract private investors.

The downstream effects are stark. Universities often retain up to half of grant allocations as overhead, siphoning resources away from the innovators themselves. Start‑ups that depend on grant cash tend to remain part‑time within academia, stretching product development timelines and missing critical market windows. Orbex’s trajectory illustrates the danger: initial private backing gave way to escalating public subsidies, yet launch milestones slipped and the company entered administration, leaving taxpayers on the hook. Conversely, firms like Proxima Fusion demonstrated that securing venture capital first forces rigorous customer and revenue validation, after which public funds can be deployed to accelerate scaling without bearing the primary risk.

A strategic pivot is needed. European policymakers should incentivize private‑first financing models, perhaps by offering matching grants only after a startup has raised a defined amount of venture capital or achieved key commercial milestones. This would preserve the essential role of public money in de‑risking early research while ensuring that taxpayer dollars amplify, rather than replace, market validation. By reshaping the funding sequence, Europe can unleash its scientific talent, produce faster‑growing companies, and strengthen its position in the global innovation race.